Find L-Arginine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: L-arginine, 74-79-3, L-(+)-arginine, L(+)-arginine, L-arg, (s)-2-amino-5-guanidinopentanoic acid
Molecular Formula
C6H14N4O2
Molecular Weight
174.20  g/mol
InChI Key
ODKSFYDXXFIFQN-BYPYZUCNSA-N
FDA UNII
94ZLA3W45F

L-Arginine
An essential amino acid that is physiologically active in the L-form.
1 2D Structure

L-Arginine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid
2.1.2 InChI
InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
2.1.3 InChI Key
ODKSFYDXXFIFQN-BYPYZUCNSA-N
2.1.4 Canonical SMILES
C(CC(C(=O)O)N)CN=C(N)N
2.1.5 Isomeric SMILES
C(C[C@@H](C(=O)O)N)CN=C(N)N
2.2 Other Identifiers
2.2.1 UNII
94ZLA3W45F
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Arginine Hydrochloride

2. Arginine, L Isomer

3. Arginine, L-isomer

4. Dl Arginine Acetate, Monohydrate

5. Dl-arginine Acetate, Monohydrate

6. Hydrochloride, Arginine

7. L Arginine

8. L-arginine

9. L-isomer Arginine

10. Monohydrate Dl-arginine Acetate

2.3.2 Depositor-Supplied Synonyms

1. L-arginine

2. 74-79-3

3. L-(+)-arginine

4. L(+)-arginine

5. L-arg

6. (s)-2-amino-5-guanidinopentanoic Acid

7. H-arg-oh

8. (l)-arginine

9. Arginina

10. Arginine, L-

11. Arginine (van)

12. L-arginin

13. Argininum [inn-latin]

14. Arginina [inn-spanish]

15. L-ornithine, N5-(aminoiminomethyl)-

16. Argamine

17. Argivene

18. Detoxargin

19. Levargin

20. L-alpha-amino-delta-guanidinovaleric Acid

21. Arg

22. Minophagen A

23. 1-amino-4-guanidovaleric Acid

24. Ccris 3609

25. (s)-(+)-arginine

26. Nsc 206269

27. Chebi:16467

28. Hsdb 1429

29. Ai3-24165

30. (s)-2-amino-5-((aminoiminomethyl)amino)pentanoic Acid

31. (s)-2-amino-5-guanidinovaleric Acid

32. Brn 1725413

33. L-norvaline, 5-((aminoiminomethyl)amino)-

34. 2-amino-5-guanidinovaleric Acid

35. Chembl1485

36. (2s)-2-amino-5-guanidinopentanoic Acid

37. (s)-2-amino-5-[(aminoiminomethyl)amino]pentanoic Acid

38. (2s)-2-amino-5-(diaminomethylideneamino)pentanoic Acid

39. 94zla3w45f

40. Pentanoic Acid, 2-amino-5-((aminoiminomethyl)amino)-, (s)-

41. (2s)-2-amino-5-(carbamimidamido)pentanoic Acid

42. L-arginine, Monohydrochloride

43. Nsc-206269

44. Arginine (l-arginine)

45. R-gene

46. L-norvaline, 5-[(aminoiminomethyl)amino]-

47. (2s)-2-amino-5-carbamimidamidopentanoic Acid

48. Dsstox_cid_21056

49. Dsstox_rid_79618

50. Dsstox_gsid_41056

51. Argininum

52. Pentanoic Acid, 2-amino-5-[(aminoiminomethyl)amino]-, (s)-

53. Arginine [usan:inn]

54. Cas-74-79-3

55. Arginine [usp:inn]

56. Einecs 200-811-1

57. Mfcd00002635

58. 2-amino-5-guanidino-pentanoic Acid

59. Unii-94zla3w45f

60. Nsc203450

61. 3h-l-arginine

62. L-arginine, Labeled With Tritium

63. 1laf

64. L-a-amino-d-guanidinovaleric Acid

65. Ncgc00015064-02

66. (s)-arginine

67. L(+) Arginine

68. L-aryginine,(s)

69. H-arg

70. L-(+) Arginine

71. L(+)-arginine;

72. L-arginine (9ci)

73. Arginine (usp/inn)

74. Tocris-0663

75. (2s)-2-amino-5-guanidino-pentanoic Acid

76. Arginine [hsdb]

77. Arginine [inci]

78. L-arginine (jp17)

79. Arginine [inn]

80. Arginine [ii]

81. Arginine [mi]

82. Arginine [vandf]

83. Gnd

84. Lopac-a-5006

85. Arginine, L- (8ci)

86. Arginine [mart.]

87. L-arginine [fcc]

88. L-arginine [jan]

89. Arginine [who-dd]

90. Bmse000029

91. Bmse000899

92. Bmse000919

93. Epitope Id:140084

94. L-arginine (h-arg-oh)

95. L-arginine [fhfi]

96. Ec 200-811-1

97. Schembl1791

98. 2-amino-5-guanidinovalerate

99. Lopac0_000077

100. Arginine Hydrochloride(usan)

101. Gtpl721

102. L-arginine [usp-rs]

103. 4-04-00-02648 (beilstein Handbook Reference)

104. L-a-amino-d-guanidinovalerate

105. L-amino-4-guanidovaleric Acid

106. Arginine [ep Impurity]

107. Us9138393, L-arginine

108. Us9144538, L-arginine

109. 1-amino-4-guanidovalerlic Acid

110. Arginine [ep Monograph]

111. Arginine [usp Monograph]

112. Dtxsid6041056

113. Bdbm21959

114. L-arginine, 99%, Fcc, Fg

115. Bdbm181132

116. Hms3260o15

117. N5-(aminoiminomethyl)-l-ornithine

118. Hy-n0455

119. Zinc1532525

120. L-arginine, Vetec(tm), 98.5%

121. Tox21_113046

122. Tox21_500077

123. Ac-083

124. L-2-amino-5-guanidinopentanoic Acid

125. L-alpha-amino-delta-guanidinovalerate

126. L-arginine, Reagent Grade, >=98%

127. S5634

128. Akos006239069

129. Akos015854096

130. Tox21_113046_1

131. Am81500

132. Ccg-204172

133. Db00125

134. Lp00077

135. Sdccgsbi-0050065.p002

136. L-arginine, 99%, Natural, Fcc, Fg

137. (s)-2-amino-5-guanidino-pentanoic Acid

138. 5-[(aminoiminomethyl)amino]-l-norvaline

139. Ncgc00015064-01

140. Ncgc00024715-01

141. Ncgc00024715-02

142. Ncgc00024715-03

143. Ncgc00024715-04

144. Ncgc00024715-05

145. Ncgc00024715-10

146. Ncgc00260762-01

147. 4455-52-1

148. As-14190

149. L-arginine, Bioultra, >=99.5% (nt)

150. Sbi-0207062.p001

151. A0526

152. A7079

153. Eu-0100077

154. L-arginine, Saj Special Grade, >=98.0%

155. A 5006

156. C00062

157. D02982

158. L-arginine, Vetec(tm) Reagent Grade, >=98%

159. Lysine Acetate Impurity F [ep Impurity]

160. M02981

161. 2-azaniumyl-5-(diaminomethyleneammonio)pentanoate

162. Ab00374192_03

163. Norvaline, 5-[(aminoiminomethyl)amino]-, (l)-

164. 002a635

165. A837397

166. A929348

167. Q173670

168. Sr-01000075479

169. Sr-01000597671

170. (s)-2-amino-5-[(aminoiminomethyl)amino]-pentanoate

171. (s)-2-amino-5-[(aminoiminomethyl)amino]pentanoate

172. Sr-01000075479-1

173. Sr-01000597671-1

174. W-104410

175. (s)-2-amino-5-[(aminoiminomethyl)amino]-pentanoic Acid

176. Arginine, European Pharmacopoeia (ep) Reference Standard

177. (2s)-2-amino-5-[(diaminomethylidene)amino]pentanoic Acid

178. 7f15b0c7-356d-45d7-ac33-03aee4394a0e

179. S-(+)-2-amino-5-[(aminoiminomethyl)amino]pentanoic Acid

180. (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic Acid

181. L-arginine, United States Pharmacopeia (usp) Reference Standard

182. L-arginine, Pharmaceutical Secondary Standard; Certified Reference Material

183. L-

184. L-arginine, From Non-animal Source, Meets Ep, Usp Testing Specifications, Suitable For Cell Culture, 98.5-101.0%

185. L-arginine, Pharmagrade, Ajinomoto, Ep, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production, Suitable For Cell Culture

2.3.3 Other Synonyms

1. L-arginine

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 174.20 g/mol
Molecular Formula C6H14N4O2
XLogP3-4.2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count4
Rotatable Bond Count5
Exact Mass174.11167570 g/mol
Monoisotopic Mass174.11167570 g/mol
Topological Polar Surface Area128 Ų
Heavy Atom Count12
Formal Charge0
Complexity176
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameR-gene 10
Active IngredientArginine hydrochloride
Dosage FormInjectable
RouteInjection
Strength10gm/100ml
Market StatusPrescription
CompanyPharmacia And Upjohn

2 of 2  
Drug NameR-gene 10
Active IngredientArginine hydrochloride
Dosage FormInjectable
RouteInjection
Strength10gm/100ml
Market StatusPrescription
CompanyPharmacia And Upjohn

4.2 Therapeutic Uses

EXPTL USE: IN MICE, L-ARGININE-HCL HAD AN INHIBITORY EFFECT ON MURINE SARCOMA VIRUS-MOLONEY & C3H BREAST ADENOCARCINOMA TUMOR SYSTEMS.

CRITSELIS AN ET AL; L-ARGININE INCREASES RESISTANCE TO TUMORS; CURR CHEMOTHER PROC INT CONGR CHEMOTHER, 10TH, VOL 2, 1978, 1122-4


EXPTL USE: EXPTL DIETS GIVEN 10 DAYS AFTER WALKER 256 CARCINOSARCOMA CELLS INOCULATED INTO RATS, RESULTED IN LOWER TUMOR WEIGHTS.

TAKAMURA C; INHIBITORY EFFECT OF ARGININE-SUPPLEMENTED DIETS ON GROWTH OF WALKER 256 CARCINOSARCOMA; KANSAI IKA DAIGAKU ZASSHI 29(3) 519 (1977)


EXPTL USE: L-ARGININE-HCL INCR IN VITRO MOTILITY IN SPECIMENS OF HUMAN SEMEN EXHIBITING SUBNORMAL MOTILITY. EFFECT WAS DOSE DEPENDENT.

KELLER DW ET AL; L-ARGININE STIMULATION OF HUMAN SPERM MOTILITY IN VITRO; BIOL REPROD 13(2) 154 (1975)


EXPTL USE: ARGININE (1% IN DIET) GIVEN TO RATS INCR THYMIC SIZE & PREVENTED THYMIC INVOLUTION WHICH OCCURS WITH INJURY. ARGININE PROMOTED WOUND HEALING IN RATS.

BARBUL A ET AL; ARGININE: A THYMOTROPIC & WOUND-HEALING PROMOTING AGENT; SURG FORUM 28: 101 (1977)


For more Therapeutic Uses (Complete) data for (L)-ARGININE (6 total), please visit the HSDB record page.


4.3 Drug Indication

Used for nutritional supplementation, also for treating dietary shortage or imbalance.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.


5.2 Absorption, Distribution and Excretion

Absorption

Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism.


5.3 Metabolism/Metabolites

Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized.


PRODUCT OF OXIDATIVE DEAMINATION OR TRANSAMINATION OF L-ARGININE IS ALPHA-KETO-GAMMA-GUANIDOVALERIC ACID; PRODUCT OF DECARBOXYLATION IS AGMATINE. PATHWAYS & PRODUCTS OF METABOLISM: ARGININE YIELDS ORNITHINE + UREA; ARGININE YIELDS CITRULLINE + NH3; ARGININE + GLYCINE YIELDS GUANIDOACETIC ACID + ORNITHINE /FROM TABLE/

Fenaroli's Handbook of Flavor Ingredients. Volume 2. Edited, translated, and revised by T.E. Furia and N. Bellanca. 2nd ed. Cleveland: The Chemical Rubber Co., 1975., p. 829


5.4 Mechanism of Action

Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.


API SUPPLIERS

read-more
read-more

01

Pfanstiehl

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF CN arrow-down AUDIT
Pfanstiehl

02

Orchid Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

Orchid Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Orchid Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

Orchid Pharma

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

AVT (Shanghai)

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

AVT (Shanghai)

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Ajinomoto Company

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

Ajinomoto Company

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

06

Ajinomoto Company

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

Ajinomoto Company

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

ACS DOBFAR SPA

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

ACS DOBFAR SPA

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

CordenPharma

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

CordenPharma

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Mitsubishi Tanabe Pharma

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

Mitsubishi Tanabe Pharma

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

CordenPharma

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

IFT FIRST
Not Confirmed
arrow

CordenPharma

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
IFT FIRST
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

Acs Dobfar Spa

Italy

USDMF

arrow
CRS
Not Confirmed

01

02

CRS
Not Confirmed

03

Ajinomoto Co Inc

Japan

USDMF

arrow
CRS
Not Confirmed

03

CRS
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-08-04

Pay. Date : 2020-11-30

DMF Number : 31646

Submission : 2017-04-20

Status : Active

Type : II

blank

04

CRS
Not Confirmed

05

Corden Pharma Latina Spa

Germany

USDMF

arrow
CRS
Not Confirmed

05

CRS
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 10131

Submission : 1989-04-07

Status : Inactive

Type : II

blank

06

Latina Pharma Spa

Germany

USDMF

arrow
CRS
Not Confirmed

06

CRS
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2014-09-04

Pay. Date : 2014-05-23

DMF Number : 28191

Submission : 2014-05-15

Status : Active

Type : II

blank

07

Tanabe Seiyaku Co Ltd

Japan

USDMF

arrow
CRS
Not Confirmed

07

08

Orchid Pharma Ltd

India

USDMF

arrow
CRS
Not Confirmed

08

CRS
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-08-09

Pay. Date : 2021-08-04

DMF Number : 18923

Submission : 2005-10-31

Status : Active

Type : II

blank

09

Orchid Pharma Ltd

India

USDMF

arrow
CRS
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

Japanese Pharmacopoeia L-Arginine (for manufacturing only)

Registration Number : 218MF10640

Registrant's Address : 1-15-1 Kyobashi, Chuo-ku, Tokyo

Initial Date of Registration : 2006-07-20

Latest Date of Registration : 2006-07-20

blank

02

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

Japanese Pharmacopoeia L-Arginine (for manufacturing only)

Registration Number : 218MF10702

Registrant's Address : 1-6-1 Otemachi, Chiyoda-ku, Tokyo

Initial Date of Registration : 2006-08-11

Latest Date of Registration : 2008-03-14

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

ARGININE

NDC Package Code : 17333-002

Start Marketing Date : 2002-06-28

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

ARGININE

NDC Package Code : 12497-1004

Start Marketing Date : 1978-03-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT FOR HUMAN P...

blank

03

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

ARGININE

NDC Package Code : 74920-003

Start Marketing Date : 2019-01-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT

blank

04

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

ARGININE

NDC Package Code : 49452-0706

Start Marketing Date : 2020-08-27

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

Pfanstiehl

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

Flag U.S.A
Digital Content Digital Content

L-Arginine

About the Company : Transform your biologic formulations with Pfanstiehl, the industry leader in High-Purity Low Endotoxin Low Metals Parenteral grade excipient manufacturing. Our expertise spans isol...

Transform your biologic formulations with Pfanstiehl, the industry leader in High-Purity Low Endotoxin Low Metals Parenteral grade excipient manufacturing. Our expertise spans isolation, purification, custom synthesis, and scale-up development, ensuring the highest quality injectable formulation ingredients. Whether you need gram-scale quantities or multi-ton batches, trust Pfanstiehl for the highest quality injectable grade excipients available. The leading pharmaceutical companies worldwide use Pfanstiehl excipients for their unmatched purity, lowest endotoxin, and minimal trace metals. Partner with us to elevate your biologics formulations
Pfanstiehl

02

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine

About the Company : Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development Zone, covering an a...

Fuan Pharmaceutical (Group) Co., Ltd. was established on February 25, 2004. The company is located in Chongqing Changshou Economic and Technological Development Zone, covering an area of about 100 acres, a construction area of over 30,000 square meters, and a registered capital of 1.189 billion yuan. It is the first company in Changshou Economic and Technological Development Zone successfully listed on the Shenzhen GEM. The company has 9 wholly-owned and holding subsidiaries. In March 2008, Fuan Pharmaceutical Group Chongqing Lybon Pharm-Tech Co
blank

03

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine

About the Company : HANGZHOU THINK CHEMICAL CO., LTD. (THINKCHEM) is an integrative corporation of trade, research and contract manufacture. With about ten years of business experiences on the marketi...

HANGZHOU THINK CHEMICAL CO., LTD. (THINKCHEM) is an integrative corporation of trade, research and contract manufacture. With about ten years of business experiences on the marketing & distribution, Thinkchem specializes in exporting pharmaceuticals, veterinary drugs, feed additives, intermediates, fine chemicals, plants extracts, pesticides, food & nutrition additives. Thinkchem is good at offering excellent outsourcing services to overseas customers as well as laboratory support. Thinkchem is equipped with modern lab apparatus including HPLC, GC. TLC AND NMR, motivated by a team of highly qualified personnel using these equipments.
blank

04

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine API

About the Company : Jing Jing Pharmaceutical Co., Ltd., founded in October 2007, covers an area of 200 mu, registered capital of 257.28 million yuan, and employees of more than 700 people, is a high-t...

Jing Jing Pharmaceutical Co., Ltd., founded in October 2007, covers an area of 200 mu, registered capital of 257.28 million yuan, and employees of more than 700 people, is a high-tech enterprise specializing in the R&D, production, and marketing of sterile raw materials, amino acids, and vitamin nutrition fortifiers. The company's technical team has obtained more than 40 patents and 7 new product and new technology appraisals. The company has formed two series of products: one is sterile API products with crystallization technology; the other is an amino acid and vitamin series product with biological enzyme catalysis technology.
blank

05

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine API

About the Company : Jing Jing Pharmaceutical Co., Ltd., founded in October 2007, covers an area of 200 mu, registered capital of 257.28 million yuan, and employees of more than 700 people, is a high-t...

Jing Jing Pharmaceutical Co., Ltd., founded in October 2007, covers an area of 200 mu, registered capital of 257.28 million yuan, and employees of more than 700 people, is a high-tech enterprise specializing in the R&D, production, and marketing of sterile raw materials, amino acids, and vitamin nutrition fortifiers. The company's technical team has obtained more than 40 patents and 7 new product and new technology appraisals. The company has formed two series of products: one is sterile API products with crystallization technology; the other is an amino acid and vitamin series product with biological enzyme catalysis technology.
blank

06

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine

About the Company : Tianjin Tianfa Pharmaceutical Import & Export Co., Ltd. (Tianfa) was established in April 2000 and is jointly funded by Tianjin Pharmaceutical Group Co., Ltd. and Jinyao Pharmaceut...

Tianjin Tianfa Pharmaceutical Import & Export Co., Ltd. (Tianfa) was established in April 2000 and is jointly funded by Tianjin Pharmaceutical Group Co., Ltd. and Jinyao Pharmaceutical Co., Ltd. Specializing in the import and export of pharmaceuticals, we offer APIs, chemical preparations, antibiotics, and more. Our corticosteroid APIs, including dexamethasone and prednisone, are exported to over 40 countries. Ranked among Tianjin’s top 50 exporters, we continuously expand our global presence and welcome collaboration to drive mutual growth.
blank

07

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine

About the Company : Yangzhou Gami Biochem Co., Ltd. is one of the leading exporters of CDCA, UDCA from China. We mainly engaged in sales of biochemical products, API, amino acids, plant extracts, food...

Yangzhou Gami Biochem Co., Ltd. is one of the leading exporters of CDCA, UDCA from China. We mainly engaged in sales of biochemical products, API, amino acids, plant extracts, food & feed additives and other chemical materials in domestic and overseas markets.We work closely with a selected group of factories in China. All the products we supply are produced and analyzed by a highly qualified and experienced team of chemists ensuring quality products to the valued clients all over the world. The dedicated people and new innovative technologies of our contracted factories have enabled our company to supply the highest quality products to our customers worldwide.
blank

08

CRS
Not Confirmed
arrow
arrow
CRS
Not Confirmed

L-Arginine

About the Company : Yichang Three Gorges Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Renfu Pharmaceutical Group, is a national high-tech biopharmaceutical enterprise specializing in antibio...

Yichang Three Gorges Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Renfu Pharmaceutical Group, is a national high-tech biopharmaceutical enterprise specializing in antibiotic APIs, high-capacity amino acid injections, and veterinary drug formulations. Recognized as a "Hidden Champion Technology Little Giant" in Hubei's key industries, the company has received accolades such as "Excellent Export Enterprise for Pharmaceutical Raw Materials" and "Top 10 Exporters for Foreign Exchange Earnings" in Hubei. Its "Three Gorges Brand" is a well-known trademark in Yichang.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Emifarma will be responsible for initial development & testing of the Company’s Mango ED products a combination of Tadalafil, Oxytocin, and L-Arginine intended for Mexican and Latin American markets.


Lead Product(s): Tadalafil,L-Arginine,Oxytocin

Therapeutic Area: Psychiatry/Psychology Brand Name: Mango ED

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Mangoceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 04, 2024

blank

01

Emifarma

Mexico
arrow
CRS
Not Confirmed

Emifarma

Mexico
arrow
CRS
Not Confirmed

Details : Emifarma will be responsible for initial development & testing of the Company’s Mango ED products a combination of Tadalafil, Oxytocin, and L-Arginine intended for Mexican and Latin American markets.

Product Name : Mango ED

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 04, 2024

blank

Details:

The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.


Lead Product(s): Tadalafil,L-Arginine,Oxytocin

Therapeutic Area: Psychiatry/Psychology Brand Name: Tadalafil Mango

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Boustead Securities

Deal Size: $1.2 million Upfront Cash: Undisclosed

Deal Type: Public Offering December 15, 2023

blank

02

CRS
Not Confirmed
CRS
Not Confirmed

Details : The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dy...

Product Name : Tadalafil Mango

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

December 15, 2023

blank

Details:

The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.


Lead Product(s): Tadalafil,L-Arginine,Oxytocin

Therapeutic Area: Psychiatry/Psychology Brand Name: Tadalafil Mango

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Greater NY Chamber of Commerce

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 08, 2023

blank

03

CRS
Not Confirmed
CRS
Not Confirmed

Details : The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.

Product Name : Tadalafil Mango

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

September 08, 2023

blank

Details:

Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.


Lead Product(s): Sildenafil Citrate,L-Arginine,Oxytocin

Therapeutic Area: Psychiatry/Psychology Brand Name: Mango

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 16, 2023

blank

04

CRS
Not Confirmed
CRS
Not Confirmed

Details : Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.

Product Name : Mango

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 16, 2023

blank

Details:

ITM-11 consists of two components: the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.


Lead Product(s): 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area: Oncology Brand Name: ITM-11

Study Phase: Phase IIIProduct Type: Radiolabelled Compounds

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 27, 2022

blank

05

CRS
Not Confirmed
CRS
Not Confirmed

Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : ITM-11 consists of two components: the medical radioisotope non-carrier-added lutetium-177 (n.c.a. 177Lu) and the targeting molecule edotreotide, a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors.

Product Name : ITM-11

Product Type : Radiolabelled Compounds

Upfront Cash : Inapplicable

October 27, 2022

blank

Details:

ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.


Lead Product(s): 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area: Oncology Brand Name: ITM-11

Study Phase: Phase IIIProduct Type: Radiolabelled Compounds

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 03, 2022

blank

06

CRS
Not Confirmed
CRS
Not Confirmed

Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.

Product Name : ITM-11

Product Type : Radiolabelled Compounds

Upfront Cash : Inapplicable

September 03, 2022

blank

Details:

Abintra features a unique combination of arginine, glutamine, high-quality protein, and antioxidant vitamins and minerals in a quick-dissolving powder. The formula works to promote tissue synthesis and wound healing from within.


Lead Product(s): L-Arginine

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Abintra

Study Phase: Approved FDFProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 24, 2022

blank

07

Megalabs

Brazil
arrow
CRS
Not Confirmed

Megalabs

Brazil
arrow
CRS
Not Confirmed

Details : Abintra features a unique combination of arginine, glutamine, high-quality protein, and antioxidant vitamins and minerals in a quick-dissolving powder. The formula works to promote tissue synthesis and wound healing from within.

Product Name : Abintra

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

August 24, 2022

blank

Details:

ITM-11 is a Targeted Radionuclide Therapy consisting of the high-quality beta-emitting radioisotope, no-carrier-added lutetium-177 (n.c.a. 177Lu) combined with the tumor-specific targeting molecule edotreotide.


Lead Product(s): 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area: Oncology Brand Name: ITM-11

Study Phase: Phase IIIProduct Type: Radiolabelled Compounds

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 15, 2022

blank

08

CRS
Not Confirmed
CRS
Not Confirmed

Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : ITM-11 is a Targeted Radionuclide Therapy consisting of the high-quality beta-emitting radioisotope, no-carrier-added lutetium-177 (n.c.a. 177Lu) combined with the tumor-specific targeting molecule edotreotide.

Product Name : ITM-11

Product Type : Radiolabelled Compounds

Upfront Cash : Inapplicable

June 15, 2022

blank

Details:

ITM-11 (n.c.a. 177Lu-edotreotide), as first- or second-line treatment compared to best standard of care for patients with well-differentiated aggressive grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.


Lead Product(s): 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area: Oncology Brand Name: ITM-11

Study Phase: Phase IIIProduct Type: Radiolabelled Compounds

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 09, 2022

blank

09

CRS
Not Confirmed
CRS
Not Confirmed

Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : ITM-11 (n.c.a. 177Lu-edotreotide), as first- or second-line treatment compared to best standard of care for patients with well-differentiated aggressive grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Product Name : ITM-11

Product Type : Radiolabelled Compounds

Upfront Cash : Inapplicable

June 09, 2022

blank

Details:

The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroendocrine tumors.


Lead Product(s): 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area: Oncology Brand Name: ITM-11

Study Phase: Phase IIIProduct Type: Radiolabelled Compounds

Sponsor: Indigenous Critical Infrastructure Fund Canada

Deal Size: $36.3 million Upfront Cash: Undisclosed

Deal Type: Financing March 22, 2022

blank

10

CRS
Not Confirmed
CRS
Not Confirmed

Lead Product(s) : 177-Lu Edotreotide,L-Arginine,Lysine

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Indigenous Critical Infrastructure Fund Canada

Deal Size : $36.3 million

Deal Type : Financing

Details : The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroe...

Product Name : ITM-11

Product Type : Radiolabelled Compounds

Upfront Cash : Undisclosed

March 22, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 74-79-3 / L-Arginine API manufacturers, exporters & distributors?

L-Arginine manufacturers, exporters & distributors 1

11

PharmaCompass offers a list of L-Arginine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right L-Arginine manufacturer or L-Arginine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred L-Arginine manufacturer or L-Arginine supplier.

PharmaCompass also assists you with knowing the L-Arginine API Price utilized in the formulation of products. L-Arginine API Price is not always fixed or binding as the L-Arginine Price is obtained through a variety of data sources. The L-Arginine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

L-Arginine

Synonyms

74-79-3, L-(+)-arginine, L(+)-arginine, L-arg, (s)-2-amino-5-guanidinopentanoic acid, H-arg-oh

Cas Number

74-79-3

Unique Ingredient Identifier (UNII)

94ZLA3W45F

About L-Arginine

An essential amino acid that is physiologically active in the L-form.

NCGC00024715-03 Manufacturers

A NCGC00024715-03 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of NCGC00024715-03, including repackagers and relabelers. The FDA regulates NCGC00024715-03 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. NCGC00024715-03 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of NCGC00024715-03 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

NCGC00024715-03 Suppliers

A NCGC00024715-03 supplier is an individual or a company that provides NCGC00024715-03 active pharmaceutical ingredient (API) or NCGC00024715-03 finished formulations upon request. The NCGC00024715-03 suppliers may include NCGC00024715-03 API manufacturers, exporters, distributors and traders.

click here to find a list of NCGC00024715-03 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

NCGC00024715-03 USDMF

A NCGC00024715-03 DMF (Drug Master File) is a document detailing the whole manufacturing process of NCGC00024715-03 active pharmaceutical ingredient (API) in detail. Different forms of NCGC00024715-03 DMFs exist exist since differing nations have different regulations, such as NCGC00024715-03 USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A NCGC00024715-03 DMF submitted to regulatory agencies in the US is known as a USDMF. NCGC00024715-03 USDMF includes data on NCGC00024715-03's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The NCGC00024715-03 USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of NCGC00024715-03 suppliers with USDMF on PharmaCompass.

NCGC00024715-03 JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The NCGC00024715-03 Drug Master File in Japan (NCGC00024715-03 JDMF) empowers NCGC00024715-03 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the NCGC00024715-03 JDMF during the approval evaluation for pharmaceutical products. At the time of NCGC00024715-03 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of NCGC00024715-03 suppliers with JDMF on PharmaCompass.

NCGC00024715-03 CEP

A NCGC00024715-03 CEP of the European Pharmacopoeia monograph is often referred to as a NCGC00024715-03 Certificate of Suitability (COS). The purpose of a NCGC00024715-03 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of NCGC00024715-03 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of NCGC00024715-03 to their clients by showing that a NCGC00024715-03 CEP has been issued for it. The manufacturer submits a NCGC00024715-03 CEP (COS) as part of the market authorization procedure, and it takes on the role of a NCGC00024715-03 CEP holder for the record. Additionally, the data presented in the NCGC00024715-03 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the NCGC00024715-03 DMF.

A NCGC00024715-03 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. NCGC00024715-03 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of NCGC00024715-03 suppliers with CEP (COS) on PharmaCompass.

NCGC00024715-03 NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing NCGC00024715-03 as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for NCGC00024715-03 API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture NCGC00024715-03 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain NCGC00024715-03 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a NCGC00024715-03 NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of NCGC00024715-03 suppliers with NDC on PharmaCompass.

NCGC00024715-03 GMP

NCGC00024715-03 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of NCGC00024715-03 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right NCGC00024715-03 GMP manufacturer or NCGC00024715-03 GMP API supplier for your needs.

NCGC00024715-03 CoA

A NCGC00024715-03 CoA (Certificate of Analysis) is a formal document that attests to NCGC00024715-03's compliance with NCGC00024715-03 specifications and serves as a tool for batch-level quality control.

NCGC00024715-03 CoA mostly includes findings from lab analyses of a specific batch. For each NCGC00024715-03 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

NCGC00024715-03 may be tested according to a variety of international standards, such as European Pharmacopoeia (NCGC00024715-03 EP), NCGC00024715-03 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (NCGC00024715-03 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty